Do analysts rate TENX or ACB?

Tenax Therapeutics currently has a consensus target price of $14.00, suggesting a potential upside of 607.07%. Given Tenax Therapeutics' higher probable upside, research analysts clearly believe Tenax Therapeutics is more favorable than Aurora Cannabis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tenax Therapeutics 1 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.40 Aurora Cannabis 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Does the media refer more to TENX or ACB?

In the previous week, Tenax Therapeutics and Tenax Therapeutics both had 3 articles in the media. Tenax Therapeutics' average media sentiment score of 0.99 beat Aurora Cannabis' score of -0.81 indicating that Tenax Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenax Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aurora Cannabis 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Negative

Is PALI or TENX more profitable?

Palisade Bio's return on equity of -33.47% beat Tenax Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Palisade Bio N/A -33.47% -31.79% Tenax Therapeutics N/A -61.54% -57.42%

Does the media favor PALI or TENX?

In the previous week, Palisade Bio had 2 more articles in the media than Tenax Therapeutics. MarketBeat recorded 5 mentions for Palisade Bio and 3 mentions for Tenax Therapeutics. Tenax Therapeutics' average media sentiment score of 0.99 beat Palisade Bio's score of 0.64 indicating that Tenax Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palisade Bio 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Tenax Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer SIGA or TENX?

Tenax Therapeutics has a consensus target price of $14.00, suggesting a potential upside of 607.07%. Given Tenax Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tenax Therapeutics is more favorable than Siga Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tenax Therapeutics 1 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.40

Does the media favor SIGA or TENX?

In the previous week, Tenax Therapeutics had 2 more articles in the media than Siga Technologies. MarketBeat recorded 3 mentions for Tenax Therapeutics and 1 mentions for Siga Technologies. Siga Technologies' average media sentiment score of 1.76 beat Tenax Therapeutics' score of 0.99 indicating that Siga Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Siga Technologies 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Tenax Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor LFCR or TENX?

In the previous week, Lifecore Biomedical had 20 more articles in the media than Tenax Therapeutics. MarketBeat recorded 23 mentions for Lifecore Biomedical and 3 mentions for Tenax Therapeutics. Tenax Therapeutics' average media sentiment score of 0.99 beat Lifecore Biomedical's score of -0.03 indicating that Tenax Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lifecore Biomedical 3 Very Positive mention(s) 4 Positive mention(s) 10 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Tenax Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, CRDL or TENX?

Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardiol Therapeutics N/A N/A -$24.20M -$0.25 N/A Tenax Therapeutics N/A N/A -$52.60M -$1.48 N/A

Is CRDL or TENX more profitable?

Tenax Therapeutics' return on equity of -61.54% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cardiol Therapeutics N/A -180.44% -140.28% Tenax Therapeutics N/A -61.54% -57.42%

Tenax Therapeutics (TENX) Competitors

$1.98 +0.05 (+2.59%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.97 -0.01 (-0.51%)

As of 10/2/2026 07:55 PM Eastern

Compare

TENX vs. ACB, PALI, SIGA, LFCR, and CRDL

Should you buy Tenax Therapeutics stock or one of its competitors? Tenax Therapeutics's main competitors and comparable companies include Aurora Cannabis (ACB), Palisade Bio (PALI), Siga Technologies (SIGA), Lifecore Biomedical (LFCR), and Cardiol Therapeutics (CRDL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Tenax Therapeutics compare to Aurora Cannabis?

Tenax Therapeutics (NASDAQ:TENX) and Aurora Cannabis (NASDAQ:ACB) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

Tenax Therapeutics has higher earnings, but lower revenue than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.48	N/A
Aurora Cannabis	$314.07M	0.82	-$88.13M	-$1.41	N/A

Tenax Therapeutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market. Comparatively, Aurora Cannabis has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market.

Tenax Therapeutics has a net margin of 0.00% compared to Aurora Cannabis' net margin of -32.26%. Aurora Cannabis' return on equity of 4.37% beat Tenax Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenax Therapeutics	N/A	-61.54%	-57.42%
Aurora Cannabis	-32.26%	4.37%	3.45%

In the previous week, Tenax Therapeutics and Tenax Therapeutics both had 3 articles in the media. Tenax Therapeutics' average media sentiment score of 0.99 beat Aurora Cannabis' score of -0.81 indicating that Tenax Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenax Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aurora Cannabis	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Negative

Tenax Therapeutics currently has a consensus target price of $14.00, suggesting a potential upside of 607.07%. Given Tenax Therapeutics' higher probable upside, research analysts clearly believe Tenax Therapeutics is more favorable than Aurora Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenax Therapeutics	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.40
Aurora Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

1.7% of Tenax Therapeutics shares are owned by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are owned by institutional investors. 10.8% of Tenax Therapeutics shares are owned by insiders. Comparatively, 0.0% of Aurora Cannabis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Tenax Therapeutics beats Aurora Cannabis on 8 of the 14 factors compared between the two stocks.

How does Tenax Therapeutics compare to Palisade Bio?

Palisade Bio (NASDAQ:PALI) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings.

Palisade Bio has a beta of 1.61, suggesting that its stock price is 61% more volatile than the broader market. Comparatively, Tenax Therapeutics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market.

Palisade Bio currently has a consensus target price of $9.83, suggesting a potential upside of 582.87%. Tenax Therapeutics has a consensus target price of $14.00, suggesting a potential upside of 607.07%. Given Tenax Therapeutics' higher possible upside, analysts clearly believe Tenax Therapeutics is more favorable than Palisade Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00
Tenax Therapeutics	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.40

Palisade Bio has higher revenue and earnings than Tenax Therapeutics. Palisade Bio is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250K	1,003.80	-$16.78M	-$0.48	N/A
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.48	N/A

Palisade Bio's return on equity of -33.47% beat Tenax Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-33.47%	-31.79%
Tenax Therapeutics	N/A	-61.54%	-57.42%

In the previous week, Palisade Bio had 2 more articles in the media than Tenax Therapeutics. MarketBeat recorded 5 mentions for Palisade Bio and 3 mentions for Tenax Therapeutics. Tenax Therapeutics' average media sentiment score of 0.99 beat Palisade Bio's score of 0.64 indicating that Tenax Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palisade Bio	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Tenax Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

11.8% of Palisade Bio shares are held by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are held by institutional investors. 0.1% of Palisade Bio shares are held by company insiders. Comparatively, 10.8% of Tenax Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Palisade Bio beats Tenax Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Tenax Therapeutics compare to Siga Technologies?

Siga Technologies (NASDAQ:SIGA) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Siga Technologies has higher revenue and earnings than Tenax Therapeutics. Siga Technologies is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Siga Technologies	$94.57M	2.57	$23.28M	-$0.05	N/A
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.48	N/A

55.4% of Siga Technologies shares are owned by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are owned by institutional investors. 2.7% of Siga Technologies shares are owned by company insiders. Comparatively, 10.8% of Tenax Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Tenax Therapeutics has a net margin of 0.00% compared to Siga Technologies' net margin of -5.19%. Siga Technologies' return on equity of -1.55% beat Tenax Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Siga Technologies	-5.19%	-1.55%	-1.32%
Tenax Therapeutics	N/A	-61.54%	-57.42%

In the previous week, Tenax Therapeutics had 2 more articles in the media than Siga Technologies. MarketBeat recorded 3 mentions for Tenax Therapeutics and 1 mentions for Siga Technologies. Siga Technologies' average media sentiment score of 1.76 beat Tenax Therapeutics' score of 0.99 indicating that Siga Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Siga Technologies	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Tenax Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tenax Therapeutics has a consensus target price of $14.00, suggesting a potential upside of 607.07%. Given Tenax Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tenax Therapeutics is more favorable than Siga Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tenax Therapeutics	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.40

Siga Technologies has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market. Comparatively, Tenax Therapeutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market.

Summary

Siga Technologies and Tenax Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Tenax Therapeutics compare to Lifecore Biomedical?

Lifecore Biomedical (NASDAQ:LFCR) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

Lifecore Biomedical currently has a consensus price target of $6.50, indicating a potential downside of 0.61%. Tenax Therapeutics has a consensus price target of $14.00, indicating a potential upside of 607.07%. Given Tenax Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tenax Therapeutics is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Tenax Therapeutics	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.40

83.4% of Lifecore Biomedical shares are owned by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are owned by institutional investors. 32.7% of Lifecore Biomedical shares are owned by insiders. Comparatively, 10.8% of Tenax Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Lifecore Biomedical has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market. Comparatively, Tenax Therapeutics has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market.

In the previous week, Lifecore Biomedical had 20 more articles in the media than Tenax Therapeutics. MarketBeat recorded 23 mentions for Lifecore Biomedical and 3 mentions for Tenax Therapeutics. Tenax Therapeutics' average media sentiment score of 0.99 beat Lifecore Biomedical's score of -0.03 indicating that Tenax Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifecore Biomedical	3 Very Positive mention(s)	4 Positive mention(s)	10 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tenax Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tenax Therapeutics has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -29.93%. Lifecore Biomedical's return on equity of 0.00% beat Tenax Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-29.93%	N/A	-16.16%
Tenax Therapeutics	N/A	-61.54%	-57.42%

Lifecore Biomedical has higher revenue and earnings than Tenax Therapeutics. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.92	-$40.50M	-$1.07	N/A
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.48	N/A

Summary

Lifecore Biomedical beats Tenax Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Tenax Therapeutics compare to Cardiol Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by insiders. Comparatively, 10.8% of Tenax Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.48	N/A

Cardiol Therapeutics presently has a consensus target price of $10.00, suggesting a potential upside of 609.22%. Tenax Therapeutics has a consensus target price of $14.00, suggesting a potential upside of 607.07%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cardiol Therapeutics is more favorable than Tenax Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Tenax Therapeutics	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.40

Cardiol Therapeutics has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market. Comparatively, Tenax Therapeutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market.

In the previous week, Tenax Therapeutics had 3 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 3 mentions for Tenax Therapeutics and 0 mentions for Cardiol Therapeutics. Tenax Therapeutics' average media sentiment score of 0.99 beat Cardiol Therapeutics' score of 0.00 indicating that Tenax Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Cardiol Therapeutics	Neutral
Tenax Therapeutics	Positive

Tenax Therapeutics' return on equity of -61.54% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-180.44%	-140.28%
Tenax Therapeutics	N/A	-61.54%	-57.42%

Summary

Tenax Therapeutics beats Cardiol Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Tenax Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TENX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TENX vs. The Competition

Export

Metric	Tenax Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$72.23M	$12.24B	$7.14B	$13.18B
Dividend Yield	N/A	2.64%	2.53%	16.78%
P/E Ratio	-1.34	799.70	275.97	26.04
Price / Sales	N/A	851.67	669.23	109.59
Price / Cash	N/A	82.26	77.60	51.75
Price / Book	0.19	10.46	10.93	6.31
Net Income	-$52.60M	$2.84B	$3.51B	$362.16M
7 Day Performance	9.39%	-1.57%	-2.00%	-1.66%
1 Month Performance	11.24%	-5.67%	-6.15%	-4.50%
1 Year Performance	-73.60%	-4.73%	7.44%	2.06%

Tenax Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TENX Tenax Therapeutics	4.4143 of 5 stars	$1.98 +2.6%	$14.00 +607.1%	-74.0%	$74.10M	N/A	N/A	16	Positive News Short Interest Decrease Gap Up
ACB Aurora Cannabis	0.9683 of 5 stars	$4.03 -1.5%	N/A	-31.0%	$265.20M	$314.07M	N/A	1,028	Analyst Upgrade
PALI Palisade Bio	2.9428 of 5 stars	$1.45 -3.3%	$9.83 +578.2%	-15.3%	$261.41M	$250K	N/A	14	Gap Up
SIGA Siga Technologies	0.4215 of 5 stars	$3.44 -0.6%	N/A	-62.2%	$248.60M	$94.57M	N/A	49	News Coverage
LFCR Lifecore Biomedical	0.5861 of 5 stars	$6.59 +1.1%	$6.50 -1.4%	-7.4%	$246.80M	$128.87M	N/A	382	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TENX) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tenax Therapeutics (TENX) Competitors

TENX vs. ACB, PALI, SIGA, LFCR, and CRDL

How does Tenax Therapeutics compare to Aurora Cannabis?

Summary

How does Tenax Therapeutics compare to Palisade Bio?

Summary

How does Tenax Therapeutics compare to Siga Technologies?

Summary

How does Tenax Therapeutics compare to Lifecore Biomedical?

Summary

How does Tenax Therapeutics compare to Cardiol Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TENX vs. The Competition

Tenax Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tenax Therapeutics (TENX) Competitors

TENX vs. ACB, PALI, SIGA, LFCR, and CRDL

How does Tenax Therapeutics compare to Aurora Cannabis?

Which has preferable earnings & valuation, TENX or ACB?

Which has more volatility and risk, TENX or ACB?

Is TENX or ACB more profitable?

Does the media refer more to TENX or ACB?

Do analysts rate TENX or ACB?

Do insiders and institutionals hold more shares of TENX or ACB?

Summary

How does Tenax Therapeutics compare to Palisade Bio?

Which has more risk & volatility, PALI or TENX?

Do analysts rate PALI or TENX?

Which has higher earnings & valuation, PALI or TENX?

Is PALI or TENX more profitable?

Does the media favor PALI or TENX?

Do insiders & institutionals have more ownership in PALI or TENX?

Summary

How does Tenax Therapeutics compare to Siga Technologies?

Which has stronger earnings & valuation, SIGA or TENX?

Do institutionals & insiders have more ownership in SIGA or TENX?

Is SIGA or TENX more profitable?

Does the media favor SIGA or TENX?

Do analysts prefer SIGA or TENX?

Which has more volatility & risk, SIGA or TENX?

Summary

How does Tenax Therapeutics compare to Lifecore Biomedical?

Do analysts recommend LFCR or TENX?

Do insiders & institutionals believe in LFCR or TENX?

Which has more risk & volatility, LFCR or TENX?

Does the media favor LFCR or TENX?

Is LFCR or TENX more profitable?

Which has higher valuation & earnings, LFCR or TENX?

Summary

How does Tenax Therapeutics compare to Cardiol Therapeutics?

Do insiders & institutionals have more ownership in CRDL or TENX?

Which has preferable valuation & earnings, CRDL or TENX?

Do analysts prefer CRDL or TENX?

Which has more volatility and risk, CRDL or TENX?

Does the media prefer CRDL or TENX?

Is CRDL or TENX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TENX vs. The Competition

Tenax Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools